RT Journal Article SR Electronic T1 Glucuronidation of Dihydroartemisinin in Vivo and by Human Liver Microsomes and Expressed UDP-Glucuronosyltransferases JF Drug Metabolism and Disposition JO Drug Metab Dispos FD American Society for Pharmacology and Experimental Therapeutics SP 1005 OP 1012 DO 10.1124/dmd.30.9.1005 VO 30 IS 9 A1 Kenneth F. Ilett A1 Brian T. Ethell A1 James L. Maggs A1 Timothy M. E. Davis A1 Kevin T. Batty A1 Brian Burchell A1 Tran Quang Binh A1 Le Thi Anh Thu A1 Nguyen Canh Hung A1 Munir Pirmohamed A1 B. Kevin Park A1 Geoffrey Edwards YR 2002 UL http://dmd.aspetjournals.org/content/30/9/1005.abstract AB The aim of this study was to elucidate the metabolic pathways for dihydroartemisinin (DHA), the active metabolite of the artemisinin derivative artesunate (ARTS). Urine was collected from 17 Vietnamese adults with falciparum malaria who had received 120 mg of ARTS i.v., and metabolites were analyzed by high-performance liquid chromatography-mass spectrometry (HPLC-MS). Human liver microsomes were incubated with [12-3H]DHA and cofactors for either glucuronidation or cytochrome P450-catalyzed oxidation. Human liver cytosol was incubated with cofactor for sulfation. Metabolites were detected by HPLC-MS and/or HPLC with radiochemical detection. Metabolism of DHA by recombinant human UDP-glucuronosyltransferases (UGTs) was studied. HPLC-MS analysis of urine identified α-DHA-β-glucuronide (α-DHA-G) and a product characterized as the tetrahydrofuran isomer of α-DHA-G. DHA was present only in very small amounts. The ratio of the tetrahydrofuran isomer, α-DHA-G, was highly variable (median 0.75; range 0.09–64). Nevertheless, α-DHA-G was generally the major urinary product of DHA glucuronidation in patients. The tetrahydrofuran isomer appeared to be at least partly a product of nonenzymic reactions occurring in urine and was readily formed from α-DHA-G by iron-mediated isomerization. In human liver microsomal incubations, DHA-G (diastereomer unspecified) was the only metabolite found (Vmax 177 ± 47 pmol min−1mg−1, Km 90 ± 16 μM). α-DHA-G was formed in incubations of DHA with expressed UGT1A9 (Km 32 μM, Vmax8.9 pmol min−1 mg−1) or UGT2B7 (Km 438 μM,Vmax 10.9 pmol mg−1min−1) but not with UGT1A1 or UGT1A6. There was no significant metabolism of DHA by cytochrome-P450 oxidation or by cytosolic sulfotransferases. We conclude that α-DHA-G is an important metabolite of DHA in humans and that its formation is catalyzed by UGT1A9 and UGT2B7. The American Society for Pharmacology and Experimental Therapeutics